6,338 Shares in Edwards Lifesciences Corporation $EW Purchased by Csenge Advisory Group

Csenge Advisory Group acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 6,338 shares of the medical research company’s stock, valued at approximately $573,000.

A number of other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $5,318,092,000. State Street Corp increased its stake in Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after acquiring an additional 371,892 shares during the period. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after acquiring an additional 989,533 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $1,274,082,000. Finally, Norges Bank bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $803,686,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 2.4%

Shares of EW stock opened at $90.02 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The stock’s fifty day moving average price is $89.12 and its two-hundred day moving average price is $84.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market cap of $51.83 billion, a PE ratio of 51.74, a P/E/G ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the firm posted $0.67 EPS. The firm’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on EW. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Citigroup boosted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Mizuho upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Finally, Truist Financial raised their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.